16 research outputs found
Prices of Orphan Drugs in Four Western European Countries Before and After Market Exclusivity Expiry:A Cross-Country Comparison of List Prices and Purchase Prices
Background: Increasing pharmaceutical expenditure challenges the sustainability and accessibility of healthcare systems across Europe. Confidentiality restraints hinder assessment of actual prices of Orphan Medicinal Products (OMPs). Hence, we assessed the real prices of brand-name OMPs around market exclusivity expiry (MEE). Objective: We aimed to explore developments in published list prices (LPs) and confidential hospital purchase prices (PPs) of brand-name OMPs relative to their market exclusivity status in Western European countries with similar GDPs. Methods: We analyzed LPs and PPs of 13 selected OMPs purchased by university hospitals in Western European countries between 2000 and 2020. For confidentially reasons, proportions were used, with the Dutch LPs of the selected OMPs at the year of MEE serving as reference values. PPs included pre-purchase discounts. Rebates were not considered. Results: Data were analyzed from hospitals in Denmark (DK) (n = 1), France (FR) (n = 1), Germany (DE) (n = 2), and the Netherlands (NL) (n = 1). Average LPs and PPs of included OMPs dropped gradually but limited over time, with no explicit price drop after MEE. LP levels differed more per country than PP levels: LP range before MEE was 164% (DE)–101% (FR) and after MEE was 135% (DE)–82% (FR); PP range before MEE was 150% (DE)–102% (FR) and after MEE was 107% (DE)–80% (FR). Overall differences between LPs and PPs were < 3% in all countries, except for Denmark. Conclusion: No evident price drops of included brand-name OMPs were observed around MEE and differences in purchase prices are modest in the selected Western European countries. Results were not subject to significance testing. More robust data are needed to strengthen negotiations with suppliers.</p
Manipulation of oral medication for children by parents and nurses occurs frequently and is often not supported by instructions
Aim: Due to a lack of age-appropriate formulations, administration of drugs to children
remains a challenge. This study aimed to identify the problems experienced in both the
outpatient setting and the clinical setting.
Methods: Between June 2017 and January 2018, we performed a cross-sectional,
prospective study at the Sophia Children’s Hospital, The Netherlands. The study comprised
of a structured interview on drug manipulations with parents visiting the outpatient clinic,
and an observational study of drug manipulations by nurses at the wards.
Results: A total of 201 questionnaires were collected, accounting for 571 drugs and 169
manipulations (30%). Drug substances that were most often mentioned as manipulated
were macrogol (n = 23), esomeprazole (n = 15), paracetamol (n = 8), methylphenidate
(n = 7) and melatonin (n = 7). Of all manipulated medicines, 93/169 (55%) were
manipulated according to the instructions or recommendations of the Summary of Product
Characteristics (SmPC) or patient information leaflet. During the observational study,
manipulation was performed by 21/35 of observed nurses (60%), of whom 11 deviated
from the hospital protocol for manipulation or SmPC (52%).
Conclusion: Manipulation was a widely used method to administer drugs to children.
Validated information regarding manipulation of drugs for both parents and nursing staff is
needed